- Home
- RNGR vs AVTX Comparison
RNGR vs AVTX Comparison
Compare RNGR & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RNGR | AVTX |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 309.1M | 248.3M |
| IPO Year | 2017 | 2015 |
Fundamental Metrics
Financial Performance| Metric | RNGR | AVTX |
|---|---|---|
| Price | $14.54 | $19.92 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $15.00 | ★ $30.14 |
| AVG Volume (30 Days) | 136.9K | ★ 354.3K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | ★ 4.93 | N/A |
| EPS | ★ 0.66 | N/A |
| Revenue | ★ $547,800,000.00 | $192,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.56 | N/A |
| P/E Ratio | $21.60 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.56 | $3.39 |
| 52 Week High | $18.45 | $20.56 |
Technical Indicators
Market Signals| Indicator | RNGR | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 62.79 | 60.33 |
| Support Level | $13.70 | $15.53 |
| Resistance Level | $13.89 | $20.45 |
| Average True Range (ATR) | 0.45 | 1.45 |
| MACD | 0.09 | 0.15 |
| Stochastic Oscillator | 90.00 | 76.69 |
Price Performance
Historical ComparisonAbout RNGR Ranger Energy Services Inc.
Ranger Energy Services Inc is a provider of onshore high-specification (high-spec) well service rigs, wireline services, and additional processing solutions and ancillary services in the United States. It offers a range of well-site services to U.S. exploration and production (E&P) companies that are fundamental to establishing and enhancing the flow of oil and natural gas throughout the productive life of a well. The segments of the group are High Specification Rigs, Wireline Services and Processing Solutions, and Ancillary Services, of which key revenue is derived from the High Specification Rigs segment.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).